Achieve Life Sciences, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $84.9 million for the six months ended June 30, 2026, compared to a loss of $25.5 million for the same period in 2025. This increase in losses is attributed to heightened general and administrative expenses, which rose to $21.7 million from $11.7 million year-over-year, largely due to increased costs associated with commercial launch preparations and stock-based compensation. Research and development expenses also decreased to $6.4 million from $13.8 million, reflecting the completion of certain clinical trials.
The company’s total assets surged to $190.4 million as of June 30, 2026, up from $41.8 million at the end of 2025, primarily due to a successful private placement in April 2026 that raised approximately $168.2 million. This influx of capital has improved Achieve's cash position, with cash and cash equivalents totaling $48.2 million, compared to $20.9 million at the end of 2025. However, the company reported a negative working capital balance of $9.4 million, indicating ongoing liquidity concerns.
Strategically, Achieve Life Sciences is focused on the development and commercialization of its product candidate, cytisinicline, aimed at addressing nicotine dependence. The company received a Complete Response Letter (CRL) from the FDA in June 2026, citing manufacturing-related deficiencies at a third-party facility. Achieve plans to resubmit its New Drug Application (NDA) in the fourth quarter of 2026, naming a new U.S.-based manufacturer, Adare Pharma Solutions, in hopes of addressing the FDA's concerns. The anticipated approval timeline for cytisinicline is now projected for the first half of 2027.
Operationally, Achieve Life Sciences is navigating a complex landscape, including ongoing disputes with Sopharma AD regarding supply agreements for cytisinicline. The company is also facing challenges related to the reliance on third-party manufacturers for production, which could impact its ability to meet regulatory requirements and commercial demands. As of June 30, 2026, Achieve had 102.9 million shares of common stock outstanding, reflecting its efforts to raise capital through equity offerings.
Looking ahead, Achieve Life Sciences remains focused on securing regulatory approval for cytisinicline while managing its financial and operational risks. The company acknowledges the need for additional funding to support its ongoing clinical development and commercialization efforts, emphasizing the importance of strategic partnerships and collaborations to enhance its market position.
About ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company dedicated to combating nicotine dependence through its product candidate, cytisinicline. Targeting the 29 million U.S. smokers and 11 million e-cigarette users, Achieve aims to address a significant health crisis. With FDA Breakthrough Therapy Designation, cytisinicline is positioned to become the first new prescription treatment for smoking cessation in nearly two decades, offering a promising solution with a favorable safety profile.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov